High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial

• Published in: Pain medicine (Malden, Mass.) Vol. 21; no. 3; pp. 576 - 585
• Main Authors: Jann, Stefano, Fazio, Raffaella, Cocito, Dario, Toscano, Antonio, Schenone, Angelo, Marfia, Gerolama Alessandra, Antonini, Giovanni, De Toni Franceschini, Luisa, Mazzeo, Anna, Grandis, Marina, Velardo, Daniele, Mataluni, Giorgia, Peci, Erdita
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.03.2020
• Subjects: Adult; Aged; Antidepressants; Antiepileptic agents; Clinical trials; Dermatitis; Diabetes; Diabetes mellitus; Diabetic Neuropathies - drug therapy; Diabetic neuropathy; Double-Blind Method; Double-blind studies; Female; Humans; Immunoglobulins; Immunoglobulins, Intravenous - therapeutic use; Immunologic Factors - therapeutic use; Influenza; Intravenous administration; Italy; Male; Middle Aged; Pain; Pain management; Patients; Polyneuropathy; Quality of life; Treatment resistance; Italy; Intravenous Immunoglobulin; Diabetic Painful Polyneuropathy; Clinical Trial; Neuropathic Pain Symptom Inventory (NPSI); Visual Analog Scale (VAS)
• ISSN: 1526-2375; 1526-4637; 1526-4637
• DOI: 10.1093/pm/pnz331

Abstract Objectives The efficacy and safety of high-dose intravenous immunoglobulin (IVIG) in treatment-resistant diabetic painful polyneuropathy (DPN) were assessed. Design This was a randomized, double-blind, placebo-controlled, multicenter trial (EudraCT 2010–023883–42). Setting This trial was conducted at eight sites in Italy with a neurology specialist level of care. Subjects Twenty-six diabetic patients with DPN who reported baseline severity of pain >60 units (mm) on a VAS scale at enrollment and were resistant to antidepressants and antiepileptic drugs were enrolled; 23 were randomized (11 in the IVIG arm and 12 in the placebo arm). All patients completed the study and were evaluated. All patients were Caucasian, 15 were male, and 21 had a diagnosis of type II diabetes. Methods IVIG (0.4 g/kg/d) or placebo was given for five consecutive days. Pain intensity (visual analog scale, Neuropathic Pain Symptom Inventory) and quality of life (36-Item Short-Form Health Survey, Clinical/Patient Global Impression of Change questionnaires) assessments were performed at visits: baseline, start of therapy (one week later), end of therapy (five days later), and follow-up (four and eight weeks later). Results The study achieved its prespecified primary end point of ≥50% pain reduction at four weeks after IVIG, achieved in seven of 11 patients (63.6%) in the IVIG group vs zero of 12 in the placebo group (P = 0.0013). Only two adverse events were reported during the study: one patient in the treatment arm reported a mild “dermatitis psoriasiform,” whereas one patient from the placebo group reported a mild “influenza.” Conclusions Treatment with IVIG at the dose given was efficacious and safe for patients with DPN resistant to standard therapies.